Classification
- Anatomical main groupJAnti-infectives for systemic use
- Therapeutic subgroupJ05
- Pharmacological subgroupJ05A
- Chemical subgroupJ05AXOther antivirals
- Chemical substanceJ05AX31Lenacapavir
Where it is registered
Each register and historical list with its number of registrations and a few of them.
United States
FDA · 5 registrations
- Sunlenca300MG BASE · tablet · Gilead Sciences INC
- Sunlenca463.5MG BASE/1.5ML · solution · Gilead Sciences INC
- Yeztugo463.5MG BASE/1.5ML · solution · Gilead Sciences INC
- Yeztugo463.5MG/1.5ML · solution · Gilead Sciences INC
Canada
Health Canada · 4 registrations
At a glance
- ATC code
- J05AX31
- ATC group
- Anti-infectives for systemic use
- Registers
- 8
- Registrations
- 23
- With their own page
- 23
- Companies
- 7
All medicines with Lenacapavir
Human medicines from every register that match Lenacapavir by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
23 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Sunlenca | United States | 300MG BASE | tablet | Marketed | Gilead Sciences INC |
| Sunlenca | United States | 463.5MG BASE/1.5ML | solution | Marketed | Gilead Sciences INC |
| Yeztugo | United States | 463.5MG/1.5ML | solution | Marketed | Gilead Sciences INC |
| Yeztugo | United States | 463.5MG BASE/1.5ML | solution | Marketed | Gilead Sciences INC |
| Yeztugo | United States | 300MG BASE | tablet | Marketed | Gilead Sciences INC |
| Sunlenca | European Union | Authorised | Gilead Sciences Ireland Unlimited Company | ||
| Sunlenca 464 MG Solucion Inyectable | Spain | 315,4 mg/ml | solución inyectable | Marketed | Gilead Sciences Ireland Unlimited Company |
| Sunlenca 300 MG Comprimidos Recubiertos con Pelicula | Spain | 306,8 mg | comprimido recubierto con película | Marketed | Gilead Sciences Ireland Unlimited Company |
| Yeytuo | European Union | Authorised | Gilead Sciences Ireland Unlimited Company | ||
| Sunlenca 300 mg filmomhulde tabletten | Netherlands | Filmomhulde tablet | Authorised | Gilead Sciences Ireland UC | |
| Sunlenca 464 mg oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Gilead Sciences Ireland UC | |
| Sunlenca | Canada | 309 MG / ML | Solution | Marketed | Gilead Sciences Canada INC |
| Sunlenca | Canada | 300 MG | Tablet | Marketed | Gilead Sciences Canada INC |
| Yeytuo 300 mg filmomhulde tabletten | Netherlands | Filmomhulde tablet | Authorised | Gilead Sciences Ireland UC | |
| Yeytuo 464 mg oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Gilead Sciences Ireland UC | |
| Sunlenca | Brazil | Authorised | Gilead Sciences Farmaceutica do Brasil Ltda | ||
| Sunlenca | Brazil | Authorised | Gilead Sciences Farmaceutica do Brasil Ltda | ||
| Sunlenca film-coated tablet 300mg | Singapore | 300mg | tablet, film coated | Authorised | Gilead Sciences Singapore Pte. LTD. |
| Sunlenca solution for injection 463.5mg/1.5ml | Singapore | 463.5mg/1.5ml | injection, solution | Authorised | Gilead Sciences Singapore Pte. LTD. |
| Yeytuo | Canada | 300 MG | Tablet | Authorised | Gilead Sciences Canada INC |
| Yeytuo | Canada | 309 MG / ML | Solution | Authorised | Gilead Sciences Canada INC |
| Sunlenca | Croatia | Authorised | |||
| Yeytuo | Croatia | Authorised |